Education
About Us
Working with TipRanks
Follow Us
Ardent Health Partners, Inc. (ARDT)
NYSE:ARDT
Top Page
Ardent Health Partners, Inc.
(NYSE:ARDT)
Select Model
Select Model
Rating:65Neutral
Price Target:
$10.50
▲(20.69% Upside)
Action:ReiteratedDate:03/05/26
The score is driven mainly by improving financial footing (deleveraging and stronger cash generation) but is held back by the 2025 profitability reset and cautious 2026 EBITDA outlook. Technically, shares show improving near-term momentum but remain below longer-term moving averages. Valuation is supportive due to a low P/E.
Positive Factors
Balance sheet deleveraging
Substantial deleveraging to roughly 0.7x debt-to-equity materially strengthens financial flexibility. Lower leverage reduces interest and refinancing risk, increases capacity for capital allocation (capex, M&A, buybacks), and improves resilience to payer or policy shocks over the next 2–6 months.
Strengthened cash generation
Sharply improved operating and free cash flow provides durable funding for debt reduction, reinvestment, and cushions margin pressure. A doubling of free cash flow in 2025 signals better cash conversion and sustainable liquidity to support strategic initiatives and navigate near-term industry headwinds.
Cost transformation and tech-driven efficiency
A scaled IMPACT cost program plus AI/virtual care initiatives drive structural margin improvement: savings target raised to $55M and AI tools cut clinician documentation time ~35%. These initiatives reduce labor reliance, lower contract labor, and create repeatable operating leverage across the hospital footprint.
Negative Factors
Profitability reset in 2026
Management's guidance implies a near-term earnings reset with 2026 EBITDA below 2025 levels, shifting the recovery timeline to 2027. This compresses margin headroom and limits internal funding for growth initiatives until earnings normalize, raising execution demands on cost programs.
Persistent payer denials & fee pressure
Ongoing payer denials and elevated professional fees are structural margin headwinds that reduce realized revenue and raise per-case costs. These pressures constrain margin sustainability and cash conversion, forcing continual operational offsets and increasing execution risk for transformation savings.
Exchange enrollment and mix headwind
A projected ~20% decline in exchange enrollment alters payer mix toward self-pay and lower-utilization coverage, producing an estimated ~$35M EBITDA headwind. This shift raises bad-debt and collection risk and structurally pressures average revenue per admission and margin recovery over the medium term.
Ardent Health Partners, Inc. (ARDT) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.24B
Dividend YieldN/A
Average Volume (3M)407.60K
Price to Earnings (P/E)9.2
Beta (1Y)0.48
Revenue Growth10.86%
EPS Growth125.05%
CountryUS
Employees19,200
SectorHealthcare
Sector Strength45
IndustryMedical - Care Facilities
Share Statistics
EPS (TTM)0.32
Shares Outstanding142,902,280
10 Day Avg. Volume333,763
30 Day Avg. Volume407,603
Financial Highlights & Ratios
PEG Ratio-0.23
Price to Book (P/B)0.74
Price to Sales (P/S)0.20
P/FCF Ratio4.81
Enterprise Value/Market Cap2.25
Enterprise Value/Revenue0.44
Enterprise Value/Gross Profit0.45
Enterprise Value/Ebitda5.58
Forecast
1Y Price Target
$12.98Price Target Upside49.20% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering9
EPS Forecast (FY)1.17
Revenue Forecast (FY)$6.58B
Ardent Health Partners, Inc. Business Overview & Revenue Model
Company DescriptionArdent Health Partners, LLC owns and operates a network of hospitals and clinics that provides a range of healthcare services in the United States. It operates acute care hospitals, including rehabilitation hospitals and surgical hospitals. The company was founded in 2001 and is based in Brentwood, Tennessee. Ardent Health Partners, LLC is a subsidiary of EGI-AM Investments, L.L.C.
How the Company Makes MoneyArdent Health Partners generates revenue primarily through patient services, which include hospital admissions, outpatient procedures, and specialty care services. The company bills patients and their insurance providers for services rendered, with revenue derived from both private insurance and government programs such as Medicare and Medicaid. Key revenue streams include inpatient services, outpatient services, diagnostic imaging, and surgical services. Additionally, Ardent may engage in partnerships with insurance companies and other healthcare organizations, allowing it to expand its service offerings and enhance its revenue opportunities. The company also focuses on operational efficiency and patient volume growth to increase its profitability.
Ardent Health Partners, Inc. Earnings Call Summary
Earnings Call Date:Mar 04, 2026
(Q4-2025)
| % Change Since: |
Next Earnings Date:May 12, 2026
Earnings Call Sentiment Positive
The call highlighted substantial progress: record annual revenue and EBITDA, a sharp increase in operating cash flow, strengthened liquidity and leverage metrics, accelerated IMPACT program savings (raised to $55M), and measurable labor and operational improvements driven by staffing optimization and technology. Management remained cautious about industry headwinds—payer denials, elevated professional fees, and exchange enrollment risk—which are expected to pressure 2026 results and were conservatively built into guidance (2026 EBITDA midpoint below 2025). Overall, the tone balances strong operational and financial execution with prudent caution around near-term policy and payer risks; management expects the benefits of IMPACT and technology to drive a return to EBITDA growth in 2027.Q4-2025 Updates
Positive Updates
Record Financial Performance
Full-year 2025 revenue of $6.3 billion, up 6% year-over-year; adjusted EBITDA of $545 million, up 9% with margin expansion of 20 basis points to 8.6%; operating cash flow of $471 million in 2025, up 49% versus 2024; Q4 operating cash flow $223 million.
Raised IMPACT Program Target
IMPACT operating transformation program now expected to contribute approximately $55 million to adjusted EBITDA in 2026 (raised from $40 million); about $5 million of IMPACT savings recognized in 2025 with the rest ramping into 2026.
Labor and Staffing Improvements
Salaried wages & benefits declined 0.4% year-over-year in Q4; SWB (salaries, wages & benefits) per adjusted admission declined 2% in Q4 after earlier growth; contract labor expenses reduced 26% to $17 million in Q4 and now account for 2.6% of SWB (lowest since 2019); agency labor FTEs reduced by ~175 in last 4 months of 2025.
Strengthened Balance Sheet and Liquidity
Total cash increased by ~ $150 million to $710 million at year-end 2025; lease-adjusted net leverage reduced ~0.5x to 2.5x (from 2.9x); total net leverage 0.8x; total available liquidity approximately $1.0 billion; total debt outstanding $1.1 billion.
Q4 Operational Wins and Efficiency
Q4 adjusted EBITDA of $134 million was ~2% above guidance midpoint; first-case on-time starts in operating rooms improved by over 10 percentage points Q4 vs Q3; surgeries were essentially flat in Q4 while adjusted admissions grew ~2% (Q4) and full-year admissions growth was 5.3% with adjusted admissions growth 2.3% (full year).
Technology and AI-Driven Care Transformation
Enterprise AI and virtual care initiatives driving efficiency: AI scribe reduces physician documentation time by 35% and is used in ~85% of patient visits; planned AI-assisted virtual care expansion to span >2,000 patient rooms by year-end; medical wearables in implemented markets reduced mortality by up to 15% and shortened length of stay by ~1/3 day.
Disciplined 2026 Guidance
Issued 2026 adjusted EBITDA guidance of $485M-$535M (midpoint $510M) and revenue guidance of $6.4B-$6.7B (~3.6% growth at midpoint); management expects core earnings growth (~4%) plus IMPACT savings to offset known headwinds and anticipates EBITDA growth resuming in 2027.
Negative Updates
Persistent Payer Denials and Professional Fee Pressure
Payer denials remained generally consistent with Q3 into Q4 (no large improvement baked into guidance); professional fees moderated to ~8% growth in Q4 from 11% in Q3 but remain elevated and are being assumed at high-single-digit levels in 2026 guidance; management annualized elevated headwinds of roughly $50 million into the 2026 base.
Exchange/Enhanced Subsidy Risk and Expected Enrollment Decline
Management is planning for a ~20% decline in HIX enrollment from expiration of enhanced subsidies, assuming ~10%-15% shift to employer coverage and the remainder to self-pay, with utilization for that cohort assumed ~30% lower; estimated exchange headwind of about $35 million to adjusted EBITDA.
2026 EBITDA Guidance Below 2025 Actual
2026 adjusted EBITDA midpoint ($510M) is below 2025 actual ($545M); jump-off base was reduced to ~$475M after annualization of headwinds (~$50M) and restoration of short-term incentive compensation (~$20M), creating near-term drag on year-over-year growth.
Timing-Related Cash Flow Headwind
Timing of payroll cycles creates an expected ~ $50 million cash flow headwind year-over-year in 2026 comparisons (a timing/timing-of-payroll effect rather than operational deterioration).
Flat Q4 Revenue and Mixed Volume Signals
Q4 revenue of $1.61 billion was essentially flat year-over-year (adjusting for prior-year New Mexico DPP benefits implies ~3% growth); surgeries were essentially flat and adjusted admissions growth in Q4 was modest (~2%).
Remaining Uncertainty on Rural Health Fund and Policy Impacts
Potential upside from the Rural Health Fund exists (management estimates ~1/3 of hospitals could qualify), but distribution timing and amounts are unclear and were not included in 2026 guidance; CMS/payer policy shifts (prior auth, Medicaid redeterminations) remain additional uncertainty.
Earlier SWB and Cost Pressure in 2025
SWB grew 6.7% in the first nine months of 2025 before Q4 improvements; while Q4 showed reversal signs, earlier cost pressure required substantial corrective actions to reach Q4 results.
Company Guidance
Ardent's 2026 guidance calls for revenue of $6.4–$6.7 billion (≈3.6% growth at the midpoint) and adjusted EBITDA of $485–$535 million (midpoint $510M), with adjusted admissions growth of 1.5%–2.5% and management expecting roughly 4% core earnings growth; the plan assumes IMPACT program savings of about $55M in 2026 (up from $40M, with ~$5M realized in 2025, implying ~ $50M incremental benefit), a modeled exchange headwind of ~$35M, a ~ $475M jump‑off base after annualizing ~ $50M of 2025 headwinds and ~$20M restoration of incentive comp, professional fee growth in the high single digits, HIX enrollment declines of ~20% (with ~10–15% shifting to employer coverage and the balance to self‑pay and ~30% lower utilization for that cohort), excludes any Rural Health Fund benefit, flags a ~$50M payroll timing cash‑flow headwind in 2026, and expects adjusted EBITDA to return to growth in 2027.Ardent Health Partners, Inc. Financial Statement Overview
Summary
Balance sheet and cash flow trends are solid (meaningful deleveraging and sharply improved free cash flow), but operating performance softened in 2025 with lower revenue, thinner margins, and weaker net income, limiting the overall strength of fundamentals.Income Statement
Revenue expanded steadily from 2022–2024, but slipped in 2025 (down ~1.9%), signaling a near-term growth pause. Profitability is positive but thin: net margin fell from ~3.5% (2024) to ~2.1% (2025), and EBITDA margin also stepped down (from ~9.6% to ~6.4%). Net income declined meaningfully in 2025 versus 2024, suggesting cost pressure and/or less favorable mix, though the business remains profitable.58
Neutral
Balance Sheet
Leverage improved substantially: debt-to-equity moved from very elevated levels in 2022–2023 (>3x) and 2024 (~2.0x) to a much healthier ~0.7x in 2025, alongside higher equity. Returns on equity remain positive but moderated (from ~18.6% in 2024 to ~8.1% in 2025), reflecting weaker earnings and/or a larger equity base. Overall, the balance sheet trend is improving, though profitability softening reduces the benefit of the deleveraging.66
Positive
Cash Flow
Cash generation strengthened: operating cash flow rose each year from 2023 to 2025, and free cash flow more than doubled in 2025 versus 2024 (strong acceleration). After negative operating and free cash flow in 2022, the business has rebuilt positive cash flow momentum. A watch-out is that free cash flow remains below net income in the latest year (free cash flow-to-net income ~0.55), implying conversion is improving but not yet consistently strong.71
Positive
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2018 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 6.32B | 5.97B | 5.41B | 5.13B | 4.16B |
| Gross Profit | 6.17B | 4.93B | 5.27B | 4.17B | 4.16B |
| EBITDA | 481.29M | 574.93M | 350.00M | 531.70M | 245.75M |
| Net Income | 135.81M | 210.34M | 50.29M | 188.91M | -143.02M |
Balance Sheet | |||||
| Total Assets | 5.29B | 4.96B | 5.10B | 4.86B | 2.75B |
| Cash, Cash Equivalents and Short-Term Investments | 709.60M | 556.78M | 437.58M | 456.12M | 59.66M |
| Total Debt | 2.26B | 2.28B | 2.40B | 2.39B | 1.26B |
| Total Liabilities | 3.61B | 3.43B | 4.02B | 3.81B | 2.03B |
| Stockholders Equity | 1.69B | 1.13B | 670.90M | 639.05M | 331.64M |
Cash Flow | |||||
| Free Cash Flow | 258.61M | 127.52M | 84.29M | -189.47M | -1.07M |
| Operating Cash Flow | 470.51M | 315.03M | 221.70M | -38.36M | 159.59M |
| Investing Cash Flow | -214.23M | -220.46M | -137.98M | 46.58M | -482.14M |
| Financing Cash Flow | -103.47M | 24.64M | -102.26M | -270.33M | 353.22M |
Ardent Health Partners, Inc. Technical Analysis
Negative
8.70
Price Trends
9.03
Negative
9.75
Negative
11.38
Negative
Market Momentum
-0.04
Positive
39.83
Neutral
40.58
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ARDT, the sentiment is Negative. The current price of 8.7 is below the 20-day moving average (MA) of 9.32, below the 50-day MA of 9.03, and below the 200-day MA of 11.38, indicating a bearish trend. The MACD of -0.04 indicates Positive momentum. The RSI at 39.83 is Neutral, neither overbought nor oversold. The STOCH value of 40.58 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ARDT.
Ardent Health Partners, Inc. Risk Analysis
Ardent Health Partners, Inc. disclosed 54 risk factors in its most recent earnings report. Ardent Health Partners, Inc. reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Ardent Health Partners, Inc. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
78 Outperform | $2.45B | 17.67 | 9.94% | 1.80% | 23.74% | -18.99% | |
65 Neutral | $1.24B | 9.15 | 18.28% | ― | 10.86% | 125.05% | |
62 Neutral | $2.02B | 12.54 | 5.57% | 1.69% | -22.96% | -59.35% | |
58 Neutral | $3.36B | -9.62 | -523.78% | ― | 3.93% | -42.22% | |
55 Neutral | $2.12B | -1.17 | -39.42% | ― | 4.58% | -61.50% | |
53 Neutral | $1.32B | 7.31 | 953.09% | ― | 15.48% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
ARDT
Ardent Health Partners, Inc.
8.70
-5.23
-37.54%
ACHC
Acadia Healthcare
22.96
-6.05
-20.85%
BKD
Brookdale Senior Living
14.14
7.99
129.92%
NHC
National Healthcare
157.73
68.09
75.96%
SEM
Select Medical
16.27
-0.26
-1.56%
AVAH
Aveanna Healthcare Holdings
6.34
0.88
16.12%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.